🔬Deep Research
AIM — AIM ImmunoTech Inc · catalysts, narrative & risks
AIM ImmunoTech Inc. (NYSE American: AIM)
Recent Catalysts (roughly July–October 2026)
The most significant recent activity centers on the company's lead candidate Ampligen® (rintatolimod) and its pancreatic cancer program:
AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →